Abstract

Background: Lichen planus is an inflammatory disease affecting skin and oral mucosa with a typical Wickham’s white striae and keratotic cap. Clobetasol propionate is a corticosteroid used for minimizing pain and discomfort associated with the disease.

Aim: To pool the data on the effectiveness of topical application of Clobetasol propionate in oral lichen planus patients.

Methodology: Search strategy was framed and relevant articles were identified through titles, abstract and full text read in PubMed and Google scholar published between 1^st January 2000 and 31^st October 2019. Other language articles were translated as required. Only randomized controlled trial, clinical studies using Clobetasol propionate in any form and dosage and assessing its effectiveness in oral lichen planus were included. Case reports and series, reviews, editorials, conference proceeding were excluded.

Results: A total of nine studies were included in the final synthesis of this review from the initial count of 88. The reasons for exclusion were duplicate articles, irrelevant titles, study design and no required data provided. All the studies favoured the use of topical clobetasol propionate in various concentrations with presence of few side effects.

Conclusion: Topical application of Clobetasol propionate is a promising drug to be used in oral lichen planus to reduce the signs and symptoms of lesion size, pain and burning sensation. The widely used concentration was 0.05% followed by 0.25%. Future studies with malignant transformation with linger follow-ups are recommended.

Keywords: Oral Lichen Planus; Corticosteroids; Clobetasol Propionate; Pain; Burning Sensation; Lesion Size

References

1. Sugerman PB., et al. “The pathogenesis of oral lichen planus”. Critical Reviews in Oral Biology and Medicine 13 (2002): 350-365.
2. Ingafou M., et al. “Oral lichen planus: A retrospective study of 690 British patients”. Oral Disease 12 (2006): 463-468.
3. Escudier M., et al. “A scoring system for mucosal disease severity with special reference to oral lichen planus”. British Journal of Dermatology 157 (2007): 765-770.
4. Krupaa RJ., et al. “Oral lichen planus: An overview”. Journal of Pharmacy and Bioallied Sciences 7 (2015): S158-161.
5. Ismail SB., et al. “Oral lichen planus and lichenoid reactions: Etiopathogenesis, diagnosis, management and malignant transformation”. Journal of Oral Science 49 (2007): 89-106.
6. Boorghani M., et al. “Oral lichen planus: clinical features, etiology, treatment and management; a review of literature”. Journal of Dental Research Dental Clinics Dental Prospects 1 (2010): 3-9.
7. Lodi G., et al. “Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation”. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 100 (2005): 164-178.
8. Wilken R., et al. “Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial”. Trials 16 (2015): 374.
9. Pels R., et al. “Clobetasol propionate--where, when, why?”. Drugs Today 7 (2008): 547-557.
10. Campisi G., et al. “A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus. A Phase IV, randomized, observer-blinded, parallel group clinical trial”. British Journal of Dermatology5 (2004): 984-990.
11. Conrotto D., et al. “Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial”. British Journal of Dermatology1 (2006): 139-145.
12. Radfar L., et al. “A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus”. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2 (2008): 187-193.
13. Corrocher G., et al. “Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus”. Journal of Clinical Periodontology3 (2008): 244-249.
14. Carbone M., et al. “Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations”. Journal of Oral Pathology and Medicine2 (2009): 227-233.
15. Sonthalia S and Singal A. “Comparative efficacy of tacrolimus 0.1% ointment and clobetasol propionate 0.05% ointment in oral lichen planus: a randomized double-blind trial”. International Journal of Dermatology11 (2012): 1371-1378.
16. Dillenburg CS., et al. “Efficacy of laser phototherapy in comparison to topical clobetasol for the treatment of oral lichen planus: a randomized controlled trial”. Journal of Biomedical Optics 6 (2014): 068002.
17. Hettiarachchi PVKS., et al. “Comparison of topical tacrolimus and clobetasol in the management of symptomatic oral lichen planus: A double-blinded, randomized clinical trial in Sri Lanka”. Journal of Investigative and Clinical Dentistry 4 (2017).
18. Arduino PG., et al. “Randomized, placebo-controlled, double-blind trial of clobetasol propionate 0.05% in the treatment of oral lichen planus”. Oral Disease5 (2018): 772-777.
19. Brown MT and Bussell JK. “Medication adherence: WHO cares?” Mayo Clinic Proceedings4 (2011): 304-314.

Citation

Citation: Meenal Jethlia., et al. “Effectiveness of Clobetasol Propionate in the Treatment of Oral Lichen Planus - A Systematic Review". Acta Scientific Dental Sciences 4.12 (2020): 47-52.

Copyright

Copyright: © 2020 Meenal Jethlia., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.